In this issue: The European Commission’s Sector Inquiry of Pharmaceuticals Kent Bernard, Feb 06, 2008 The EC Sector Inquiry Regarding Pharmaceuticals: Some Thoughts from a U.S. Perspective When a major competition authority such as the European Commission launches an inquiry into a sector of the economy with no suggestion of specific wrongdoing, it raises a […]
This article is part of a Chronicle. See more from this Chronicle Susan Creighton, Scott Russell, Feb 14, 2008 The pharmaceutical industry remains under close examination by antitrust enforcers on both sides of the Atlantic. The U.S. Federal Trade Commission’s (FTC) enforcement activities – challenging both unilateral and concerted action undertaken by pharmaceutical firms – […]
This article is part of a Chronicle. See more from this Chronicle Luc Gyselen, Feb 14, 2008 Since the entry into force of Regulation 1/2003 on May 1, 2004, the Commission has already launched four comprehensive sector inquiries on the basis of Article 17. They concerned, respectively, energy, retail banking, and business insurance (June 2005) […]
The EC’s Investigation into the Pharmaceutical Sector: Trouble Ahead at the IP/Competition Intersection?
This article is part of a Chronicle. See more from this Chronicle David Hull, Feb 07, 2008 Efforts by innovative pharmaceutical companies to protect their markets against generic drugs have generated a wide-ranging debate over how to achieve the proper balance between these companies’ legitimate interests in reaping the full rewards of their research and […]
Non-contractual liability of the European Community in competition matters: The aftermath of the CFI judgment of 11 July 2007 in Case T-351/03, Schneider v. Commission
This article is part of a Chronicle. See more from this Chronicle Aitor Montesa Lloreda, Feb 05, 2008 The recent European Court of First Instance (CFI) judgment of July 11, 2007 in Case T-351/03, Schneider v. Commission, is the first EC judgment to grant a company damages for the losses it had suffered as a […]
This article is part of a Chronicle. See more from this Chronicle Kent Bernard, Feb 06, 2008 On January 16, 2008, the European Commission launched a sector inquiry by staging dawn raids on a number of pharmaceutical companies. When a major competition authority such as the Commission launches an “inquiry” into a sector of the […]